← Eichor
Study identifier: NCT06292897 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

Condition: Prostate Cancer · Prostate Adenocarcinoma · Prostate Neoplasm  ·  Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

PhaseN/A
Planned participants25
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Evaluate the protein expression of lactate dehydrogenase enzyme (LDHA) and MCT-1/-4 transporters, involved in lactate synthesis and transport, in prostate carcinoma tissues from severely overweight/obese (BMI \> 27.5) and non-severely overweight/normoweight (BMI \< 27.5) patients affected by prostate carcinoma. ii. Characterize the immune infiltrate in the prostate carcinoma of the aforementioned patients. iii. Assess the association between intra-tumoral lactate accumulation (using LDHA and MCT-4 protein expression levels as readouts) and alterations in the tumor immune microenvironment and/or deregulation of relevant oncogenic pathways.

This description comes directly from the study's public registry record.

Talk to the study team

Giancarlo Albo, MD,  ·  00390255034501  ·  giancarlo.albo@policlinico.mi.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Cà Granda Ospedale Maggiore Policlinico MilanoMilan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06292897